PECAM1 and kidney cancer: Both SHetA2 and palbociclib appeared to reduce tumor angiogenesis in the animal model based on the development of dilated CD31-negative blood vessels in the treated tumors, which is consistent with previous observations of SHetA2 anti-angiogenesis activity in kidney cancer xenografts [15].